Needham Reiterates Buy Rating on VRDN
Needham maintains its buy rating on VRDN with a $34 price target, a 80.95% upside from the current price.
Key Points
- Needham reiterated its buy rating on VRDN with a $34 price target on June 30, 2026.
- Needham's $34 price target implies 80.95% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.79 share price.
- Shares of VRDN traded at $18.79 on Tuesday, with major institutional investors increasing their stakes.
- Analysts from Wells Fargo and RBC Capital also maintain positive ratings on VRDN.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Needham has reiterated its buy rating on VRDN, setting a price target of $34. The announcement came on June 30, 2026, with Needham analyst Serge Belanger backing the decision. VRDN shares traded at $18.79 on Tuesday.
Needham vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in VRDN
Several major funds have shown interest in VRDN. FMR LLC increased its holdings by 994,921 shares, bringing its total to 15,379,377 shares, valued at approximately $300.8 million. BlackRock, Inc. also added 1,399,552 shares, upping its stake by 21.8% to 7,831,475 shares, worth about $153.2 million. Bellevue Group AG made a notable move, boosting its position by 2,367,617 shares to 6,726,144 shares, valued at $131.6 million. State Street Corp increased its shares by 1,206,325, ending with 4,672,885 shares valued at $91.4 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 4,167,201 shares, valued at $81.5 million.
Viridian Therapeutics, Inc. Stock Down 18.9%
On Tuesday, shares of VRDN traded around $18.79. The stock has seen notable activity from institutional investors, which is often a sign of confidence in the company's prospects.
$VRDN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Viridian Therapeutics, Inc.
Insider activity at VRDN included purchases and sales. Fairmount Funds Management LLC bought 1,176,470 shares on May 11, 2026, at an average price of $17. On March 3, 2026, several executives, including Chief Legal Officer Jennifer Tousignant, sold shares at $30.19 each. However, Tousignant also purchased 5,169 shares on the same day, indicating varied insider sentiment.
Analysts Set New Price Targets
Analysts have been active in setting targets for VRDN. On June 30, 2026, Needham maintained its buy rating with a $34 target. A day earlier, Wells Fargo upgraded VRDN to a buy with a $31 target. Other firms like Evercore ISI Group and RBC Capital have maintained positive ratings, with targets ranging from $26 to $34.
Bottom Line
Needham's reiterated buy rating and $34 target for VRDN reflect continued confidence in the company's potential. Institutional investors have been increasing their stakes, indicating a positive outlook. While insider trading offers mixed signals, the overall analyst consensus remains favorable. As always, it's important to remember that 13F filings and analyst ratings are backward-looking and may not reflect the current market conditions.
Get Viridian Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.